Join our Newsletter
From medical white papers to invite only networking, join our newsletter to stay connected with the world of CRC.
Alzheimer’s
Expertise
specialized expertise
At CRC, we deliver precise, reliable data for Alzheimer’s research, fast. Our expertise ensures that the data you receive is not only accurate but also actionable—helping you make critical decisions quickly. With a dedicated team of experts, we’re committed to supporting every phase of your research. From trial setup to final analysis, we’re here to ensure your study moves forward smoothly. Trust us to support your mission with the urgency and precision it deserves.
30+
AAMI TO SEVERE ALZHEIMER’S
PROGRAMS, PHASE I-III
5+
AGITATION ASSOCIATED WITH DEMENTIA PROGRAMS
30+
YEAR PARTNERSHIP WITH LEADING KOLs IN ALZHEIMER’S
Endpoint Expertise
Including:
BIOMARKER EXPERTISE
- Amyloid Beta Peptides (CSF & Serum)
- Neurofilament Light Chain
- PET Imaging (Amyloid & Tau)
- MRI Brain Volumetrics
- Inflammatory Biomarkers
- Quantitative EEG and ERP
COGNITIVE & FUNCTIONAL
- MMSE
- ADAS-Cog
- CDR
- ADCS-CGI
- SDB
- ADCS-ADL
- FAST
- QoL-AD
- RBAN
NEUROBEHAVIORAL ASSESSMENT
- NPI
- CMAI
- EAS
Recent CRC
RElated Publications
Safety and tolerability of GRF6019 infusions in Severe Alzheimer’s Disease:
A Phase II Double-Blinded Placebo-Controlled Trial
Journal of Alzheimer’s Disease, 2021
Safety and tolerability of GRF6019 in mild-to-moderate Alzheimer’s disease dementia
Alzheimer’s and Dementia, 2020
get in touch